Leaflet MENJUGATE lyophilisate+solvent for injection suspension


Indicated for: prevention of meningococcal disease

Route of administration: injectable

Substance: meningococcal vaccine (vaccine)

ATC: J07AH07 (Antiinfectives for systemic use | Bacterial vaccines | Meningococcal vaccines)

The meningococcal vaccine is used to prevent infections caused by the Neisseria meningitidis bacteria, which can lead to bacterial meningitis and other severe infections, such as sepsis. These conditions can progress rapidly and be life-threatening, especially in children, adolescents, and individuals with weakened immune systems.

The vaccine provides protection against several meningococcal serogroups, most commonly A, C, W, Y, and B. There are different types of meningococcal vaccines, including conjugate and recombinant vaccines, which are recommended based on age, health status, and risk of exposure.

It is usually administered in one or more doses, depending on the type of vaccine and vaccination schedule. The vaccine is well-tolerated, with side effects generally being mild, such as redness or pain at the injection site, mild fever, or fatigue.

Meningococcal vaccination is particularly recommended for infants, adolescents, travelers to high-risk areas, and individuals with medical conditions that increase their vulnerability to meningococcal infections. It is an important preventive measure to reduce the risk of severe diseases and associated complications.

General data about MENJUGATE

  • Substance: meningococcal vaccine
  • Date of last drug list: 01-07-2013
  • Commercial code: W43500003
  • Pharmaceutical form: lyophilisate+solvent for injection suspension
  • Quantity: 10
  • Product type: generic
  • Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).